Medically reviewed by Drugs. Last updated on Dec 30, Initial dose: to mcg per day, IV or subcutaneously, in 2 to 4 divided doses Comments : -The median daily dose was mcg; mean daily dose was mcg. Long-Acting depot formulation Establish tolerability with short acting product for at least 2 weeks before using this formulation : Initial dose: 20 mg, IM intragluteally , at 4 week intervals, for 2 months; continue with dose of regular octreotide for at least 2 weeks at same dose patient was on before the switch After 2 months : -If symptoms are controlled, consider reducing dose to 10 mg every 4 weeks -If symptoms are not adequately controlled, increase to 30 mg every 4 weeks Maximum dose: 30 mg every 4 weeks Comments : -Failure to continue dosing of regular octreotide during a switch to the long acting formulation may exacerbate symptoms; some patients require 3 to 4 weeks of concomitant dosing. Use: Symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease.
|Published (Last):||26 September 2016|
|PDF File Size:||10.71 Mb|
|ePub File Size:||15.63 Mb|
|Price:||Free* [*Free Regsitration Required]|
Severe diarrhea and flushing due to metastatic carcinoid tumors. Profuse watery diarrhea due to vasoactive intestinal peptide-secreting tumors VIPomas. Cardiovascular disease. Renal or hepatic impairment. Monitor thyroid function, gallbladder, glucose, vitamin B Pregnancy Cat. Nursing mothers. Antagonizes cyclosporine. Not compatible with TPN solutions.
May need to adjust antidiabetic agents. May affect agents used to control fluid and electrolyte balance. Gallbladder abnormalities eg, gallstones, biliary sludge , GI upset, bradycardia, conduction abnormalities, arrhythmias, hyperglycemia, hypoglycemia, hypothyroidism, headache, dizziness, pancreatitis, back pain, inj site pain.
Acromegaly unresponsive to or that cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. Initially 50mcg 3 times daily. Usual maintenance: micrograms 3 times daily; max mcg 3 times daily. Reevaluate every 6 months.
Monitor growth hormone, IGF-1 levels, thyroid function, gallbladder, glucose, vitamin B Discontinue and treat if cholelithiasis complications are suspected.
Children: Not recommended. Pharmacologic Class: Somatostatin analogue. Adverse Reactions: Gallbladder abnormalities eg, gallstones, biliary sludge , GI upset, bradycardia, conduction abnormalities, arrhythmias, hyperglycemia, hypoglycemia, hypothyroidism, headache, dizziness, pancreatitis, back pain, inj site pain. Enter Zip Code GoodRx. Certain Sandostatin Strengths Discontinued. Popular Emailed Recent Loading
Therapeutic Applications of Octreotide in Pediatric Patients
We report our experience with the use of octreotide as primary or adjunctive therapy in children with various gastrointestinal disorders. A pharmacy database identified patients who received octreotide for gastrointestinal diseases. Indications for octreotide use, dosing, effectiveness, and adverse events were evaluated by chart review. A total of 21 patients 12 males , aged 1 month to 13 years, were evaluated. The child with dumping syndrome responded to octreotide in a week. Adverse events developed in 4 patients: Q-T interval prolongation and ventricular fibrillation, hyperglycemia, growth hormone deficiency, and hypertension.